Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults

An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol - antivirals that are used in some countries against HIV-1 and to treat influenza, respectively - as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news